You Position: Home > Paper
The treatment of relapsed and refractory Hodgkin lymphoma
( views:480, downloads:200 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 1
- DOI:
- 10.3760/cma.j.issn.1009-9921.2008.01.003
- Key Word:
- 霍奇金淋巴瘤;复发性;难治性;治疗
Abstract： 复发性和难治性霍奇金淋巴瘤(HL)目前是治疗的难点.根据再次分期的结果和临床特点,可以采用挽救性放疗、新的化疗方案等手段,但对部分患者仍不能达到满意的疗效.新的化疗方案,包括吉西他滨、长春瑞滨等以及有新的作用机制的药物,如硼替佐米等已初见成效.大剂量化疗配合自体干细胞移植能够明显提高疗效,已经作为难治性或1年内复发的HL的常规治疗.靶向药物如利妥昔单抗对于HL,尤其是结节性淋巴细胞为主型的HL患者疗效明确.
- [1]Anas, Younes,Barbara, Pro,Luis, Fayad.Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.[J].2006,107(4).
- [2]Ribrag, V.,Nasr, F.,Bouhris, J.H.,etc.VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.[J].1998,21(10).
- [3]Pastor M,Oltra A,Aparicio J,etc.ESHAP is an active regimen for relapsing Hodgkin's disease.[J].1999,10(5).
- [4]Bradley C, Ekstrand,Jennifer B, Lucas,Steven M, Horwitz,etc.Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.[J].2003,101(11).
- [5]Cooper DL,Seropian S,Argiris A.High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.[J].2000,11(6).
- [6]Colwill R,Danish R,Couture F,etc.Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.[J].1995,13(2).
- [7]Schmitz Norbert,Pfistner Beate,Sextro Michael,etc.Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.[J].2002,359(9323).
- [8]Kars A,Tekuzman G,Koc Y,etc.Ifosfamide, Idarubicin, and Etoposide in Relapsed/Refractory Hodgkin Disease or Non-Hodgkin Lymphoma: A Salvage Regimen with High Response Rates before Autologous Stem Cell Transplantation.[J].2005,11(9).
- [9]Gunilla Enblad,Hans Hagberg,Anita Gustavsson,etc.Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study[J].1998,60(3).
- [10]Majhail NS,Weisdorf DJ,Defor TE,etc.Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.[J].2006,12(10).
- [11]C H, Moskowitz,S D, Nimer,A D, Zelenetz,etc.A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.[J].2001,97(3).
- [12]J, Rodriguez,M A, Rodriguez,L, Fayad,etc.ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease.[J].1999,93(11).
- [13]Magagnoli M,Nozza A,Pinotti G,etc.Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.[J].2007,92(1).
- [14]J. Szántó,T. Fleischmann,S. Eckhardt.Treatment of Resistant Hodgkin’s Disease with CCNU, Etoposide and Prednimustine (CEP)[J].1991,48(6).
- [15]Di Iulio J,MacManus M,Campbell B,etc.Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.[J].2005,63(5).
- [16]Ding K,Iglesias J,Couban S,etc.Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.[J].2003,14(12).
- [17]Diehl V,Hossfeld DK,Mapara M,etc.Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.[J].2002,13(10).
- [18]M C, Fernández-Jiménez,M A, Canales,E, Ojeda,etc.Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.[J].1999,84(11).